Revvity, Inc. (RVTY)
NYSE: RVTY · Real-Time Price · USD
112.56
+2.02 (1.83%)
Dec 20, 2024, 4:00 PM EST - Market closed
Revvity Employees
Revvity had 11,500 employees as of December 31, 2023. The number of employees decreased by 5,200 or -31.14% compared to the previous year.
Employees
11,500
Change (1Y)
-5,200
Growth (1Y)
-31.14%
Revenue / Employee
$236,657
Profits / Employee
$22,113
Market Cap
13.70B
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 11,500 | -5,200 | -31.14% |
Dec 31, 2022 | 16,700 | 0 | - |
Dec 31, 2021 | 16,700 | 2,700 | 19.29% |
Dec 31, 2020 | 14,000 | 1,000 | 7.69% |
Dec 31, 2019 | 13,000 | 500 | 4.00% |
Dec 31, 2018 | 12,500 | 1,500 | 13.64% |
Dec 31, 2017 | 11,000 | 3,000 | 37.50% |
Dec 31, 2016 | 8,000 | 0 | - |
Dec 31, 2015 | 8,000 | 300 | 3.90% |
Dec 31, 2014 | 7,700 | 100 | 1.32% |
Dec 31, 2013 | 7,600 | 100 | 1.33% |
Dec 31, 2012 | 7,500 | 300 | 4.17% |
Dec 31, 2011 | 7,200 | 1,000 | 16.13% |
Dec 31, 2010 | 6,200 | -2,000 | -24.39% |
Dec 31, 2009 | 8,200 | 300 | 3.80% |
Dec 31, 2008 | 7,900 | -800 | -9.20% |
Dec 31, 2007 | 8,700 | 200 | 2.35% |
Dec 31, 2006 | 8,500 | 500 | 6.25% |
Dec 31, 2005 | 8,000 | -2,000 | -20.00% |
Dec 31, 2004 | 10,000 | 0 | - |
Dec 31, 2003 | 10,000 | -700 | -6.54% |
Dec 31, 2002 | 10,700 | -100 | -0.93% |
Dec 31, 2001 | 10,800 | -1,700 | -13.60% |
Dec 31, 2000 | 12,500 | 500 | 4.17% |
Dec 31, 1999 | 12,000 | -1,000 | -7.69% |
Dec 31, 1998 | 13,000 | -1,000 | -7.14% |
Dec 31, 1997 | 14,000 | -1,000 | -6.67% |
Dec 31, 1996 | 15,000 | 0 | - |
Dec 31, 1995 | 15,000 | -10,000 | -40.00% |
Dec 31, 1994 | 25,000 | -7,000 | -21.88% |
Dec 31, 1993 | 32,000 | - | - |
Sources: Annual number of employees according to filings submitted to the U.S. Securities and Exchange Commission (SEC). Data is also manually gathered from company press releases, IPO filings, and other official sources.
Related Stocks
Company Name | Employees |
---|---|
Fresenius Medical Care AG | 119,845 |
Viatris | 38,000 |
Dr. Reddy's Laboratories | 27,048 |
Avantor | 7,570 |
Incyte | 2,524 |
Genmab | 2,204 |
Neurocrine Biosciences | 1,400 |
Insmed | 912 |
RVTY News
- 4 days ago - Revvity to Present at J.P. Morgan Healthcare Conference - Business Wire
- 6 days ago - Safe Biopharma: Revvity's Recurring Revenues And Diagnostics - Seeking Alpha
- 8 days ago - Despite Higher Valuations, Some Life Sciences Tools Stocks Create Good Opportunities: Analyst - Benzinga
- 4 weeks ago - Revvity Broadens Relationship with Genomics England to Advance Genomics in the UK - Business Wire
- 4 weeks ago - Scale Biosciences and Revvity's BioLegend Launch First-of-its-Kind Solution for High Parameter Protein Profiling of Single Cells - Business Wire
- 4 weeks ago - Revvity to Present at 7th Annual Evercore ISI HealthCONx Conference - Business Wire
- 4 weeks ago - Revvity to Host Investor Day and Updates Organizational Structure to Reflect Recent Transformation - Business Wire
- 6 weeks ago - These Analysts Revise Their Forecasts On Revvity Following Q3 Results - Benzinga